3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
40
Colorectal Neoplasms
9
Adenocarcinoma
8
Esophageal Neoplasms
7
Carcinoma, Hepatocellular
7
Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Adenocarcinoma Of Esophagus
5
Neoplasm Metastasis
4
Rectal Neoplasms
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Biliary Tract Neoplasms
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Metastatic Gastric Adenocarcinoma
2
Melanoma
2
Cholangiocarcinoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Lymphoma, Mantle-Cell
1
Locally Advanced Unresectable Gastric Adenocarcinoma
1
Liver Diseases
1
Head and Neck Neoplasms
1
HER2-positive Gastric Cancer
1
Interventions
pembrolizumab
36
Capecitabine
28
Trastuzumab
23
Paclitaxel
22
Surveys and Questionnaires
20
Cyclophosphamide
20
Gemcitabine
18
Docetaxel
18
Carboplatin
15
Nivolumab
14
Methods
14
Magnetic Resonance Spectroscopy
13
Early Intervention, Educational
13
Bevacizumab
13
Interviews as Topic
12
Blood Specimen Collection
12
fludarabine
11
Standard of Care
11
Irinotecan
11
olaparib
10
durvalumab
10
Specimen Handling
10
Psychiatric Rehabilitation
10
palbociclib
9
aldesleukin
9
Taxes
9
Fulvestrant
9
Fluorouracil
9
Exercise
9
Drug Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Ramucirumab
×
Gastrointestinal
×
Clear all
NCT02791334
2024-09-27
PACT
Eli Lilly and Company
Phase 1
Completed
164 enrolled